American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged…

By M. Hammond, D. Hayes, Mitchell Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, N. Goldstein, M. Hayes and 22 more. Archives of Pathology & Laboratory Medicine, 2010

894 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/0f0fb46adff5b4b7bff155ff14003025599ec9d0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Lisa A. Carey
2. N. Howlader
3. Charles M. Perou
4. S. Altekruse
5. K. Allison
6. Christopher I. Li
7. V. Chen
8. Kathleen A. Cronin

Citations in the corpus

• Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (2020, methodology): “determine hormone receptor status, including (but not necessarily limited to): specific assay performance, technique, standardization attempted, QA, proficiency testing, individual or institutional training, or improvement in assay results based on interventions Articles were excluded from the syste”
• US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. (2014, methodology): “%) were used for the ER/PR test, whereas cutoffs as high as 10% had previously been used for determining ER/PR positivity (20).”